# Cabaletta Bio, Inc.: overview CABA · Nasdaq · CIK 1759138 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/caba.md) · [Financials](/companies/caba/financials.md) · [Filings](/companies/caba/filings.md) · [Insiders](/companies/caba/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.62)](/filings/0001193125-25-273280.md) | not reported | [(0.71)](/filings/0001759138-26-000026.md) | [(0.73)](/filings/0001759138-26-000039.md) | [(0.44)](/filings/0001193125-25-273280.md) | not reported | [(0.39)](/filings/0001759138-26-000026.md) | [(0.34)](/filings/0001759138-26-000039.md) | | Free cash flow | $m | [(20.6) d](/filings/0001193125-25-273280.md) | [(23.5) d](/filings/0001759138-26-000011.md) | [(31.6)](/filings/0001759138-26-000026.md) | [(30.6) d](/filings/0001759138-26-000039.md) | [(34.6) d](/filings/0001193125-25-273280.md) | [(35.5) d](/filings/0001759138-26-000011.md) | [(42.6)](/filings/0001759138-26-000026.md) | [(41.5) d](/filings/0001759138-26-000039.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.80)](/filings/0000950170-23-008298.md) | [(1.81)](/filings/0000950170-24-034422.md) | [(1.65)](/filings/0000950170-25-047201.md) | [(2.34)](/filings/0001759138-26-000011.md) | [(2.10)](/filings/0001759138-26-000011.md) | | Free cash flow | $m | [(35.3)](/filings/0000950170-23-008298.md) | [(48.8)](/filings/0000950170-24-034422.md) | [(54.2)](/filings/0000950170-25-047201.md) | [(90.4)](/filings/0001759138-26-000011.md) | [(132)](/filings/0001759138-26-000011.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/caba/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JENNISON ASSOCIATES LLC](/funds/53417.md) | 2026-06-30 | $62.3m | 20,033,730 | | Added +11,063,152 | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $53.6m | 17,241,445 | | Added +7,564,320 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $33.4m | 10,754,701 | | Added +8,381,698 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $28.5m | 9,174,758 | | Added +345,000 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $24.4m | 7,839,305 | | Added +7,369,327 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $22.5m | 7,227,018 | | Added +3,198,027 | | [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $15.6m | 5,000,000 | | Reduced −500,000 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $13.1m | 4,200,142 | | Added +2,949,900 | | [NORGES BANK](/funds/1374170.md) | 2026-06-30 | $12.8m | 4,112,401 | | New +4,112,401 | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $12.0m | 3,863,800 | | Added +2,483,800 | ## Recent filings [All 435 filings](/companies/caba/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-14 | 08:00 ET | [8-K](/filings/0001759138-26-000041.md) | 8.01 Other events | 0001759138-26-000041 | | 2026-08-13 | 07:34 ET | [10-Q](/filings/0001759138-26-000039.md) | Quarterly report, period 2026-06-30 | 0001759138-26-000039 | | 2026-08-13 | 07:32 ET | [8-K](/filings/0001759138-26-000038.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759138-26-000038 | | 2026-06-11 | 07:01 ET | [8-K](/filings/0001759138-26-000033.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001759138-26-000033 | | 2026-06-03 | 07:02 ET | [8-K](/filings/0001759138-26-000030.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001759138-26-000030 | | 2026-05-14 | 07:08 ET | [10-Q](/filings/0001759138-26-000026.md) | Quarterly report, period 2026-03-31 | 0001759138-26-000026 | | 2026-05-14 | 07:06 ET | [8-K](/filings/0001759138-26-000025.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001759138-26-000025 | | 2026-05-14 | 07:02 ET | [8-K](/filings/0001759138-26-000024.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001759138-26-000024 | | 2026-05-04 | 06:40 ET | [8-K](/filings/0001193125-26-202446.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-202446 | | 2026-05-04 | 06:02 ET | [8-K](/filings/0001193125-26-202389.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-202389 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001759138-26-000011.md), filed Mar 23, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1759138 - Tickers: CABA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:27 ET. No prices; not investment advice.